Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Reports Positive Data in EP-104GI EoE Trial
Details :
Product Name : EP-104GI
Product Type : Steroid
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Announces Positive Data from Phase 1b/2a Trial of EP-104GI
Details :
Product Name : EP-104GI
Product Type : Steroid
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Shares Data from Phase 1b/2a Trial of EP-104GI for Eosinophilic Esophagitis
Details :
Product Name : EP-104GI
Product Type : Steroid
Upfront Cash : Inapplicable
November 09, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Raymond James Ltd
Deal Size : $30.0 million
Deal Type : Public Offering
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approx $30 Million
Details :
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Undisclosed
November 03, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Raymond James Ltd
Deal Size : $30.0 million
Deal Type : Public Offering
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $44.5 million
Deal Type : Private Placement
Eupraxia Closes C$44.5M Non-Brokered Private Placement
Details :
Product Name : EP-104GI
Product Type : Steroid
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $44.5 million
Deal Type : Private Placement
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Trial of EP-104GI
Details :
Product Name : EP-104GI
Product Type : Steroid
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Raymond James Ltd
Deal Size : $33.9 million
Deal Type : Public Offering
Eupraxia Pharmaceuticals Closes Overnight Offering for Gross Proceeds Of C$33.9M
Details :
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Undisclosed
March 15, 2024
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Raymond James Ltd
Deal Size : $33.9 million
Deal Type : Public Offering
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
Details :
Product Name : EP-104IAR
Product Type : Steroid
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable